Glenmark Pharmaceutical has completed successfully phase-IIb trials in 494 patients for its novel molecule Melogliptin for type-2 diabetes and the Global phase-III trial is likely to start by end of 2009. Melogliptin improves glucose control and normal pancreatic function. Melogliptin is likely to be launched in 2013.
The details can be read here.
No comments:
Post a Comment